ArticlePharmaceutical research2006
Fractal michaelis-menten kinetics under steady state conditions: Application to mibefradil.
Article in Pharmaceutical research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 26 citations in OpenAlex.
- Crowding Effects of Polystyrene Nanoparticles on Lactate Dehydrogenase Activity in Hydra Attenuata.Journal of xenobiotics · 2020Article
- Monte Carlo simulations in drug release.Journal of pharmacokinetics and pharmacodynamics · 2019Review
- The changing face of the rate concept in biopharmaceutical sciences: from classical to fractal and finally to fractional.Pharmaceutical research · 2011Article
- A new approach to the compartmental analysis in pharmacokinetics: fractional time evolution of diclofenac.Journal of pharmacokinetics and pharmacodynamics · 2010Article
- Fractional kinetics in drug absorption and disposition processes.Journal of pharmacokinetics and pharmacodynamics · 2009Article
- Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts.The AAPS journal · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo provide the first application of fractal kinetics under steady state conditions to pharmacokinetics as a model for the enzymatic elimination of a drug from the body. MATERIALS AND
methodsA one-compartment model following fractal Michaelis-Menten kinetics under a steady state is developed and applied to concentration-time data for the cardiac drug mibefradil in dogs. The model predicts a fractal reaction order and a power law asymptotic time-dependence of the drug concentration, therefore a mathematical relationship between the fractal reaction order and the power law exponent is derived. The goodness-of-fit of the model is assessed and compared to that of four other models suggested in the literature.
resultsThe proposed model provided the best fit to the data. In addition, it correctly predicted the power law shape of the tail of the concentration-time curve.
conclusionA simple one-compartment model with steady state fractal Michaelis-Menten kinetics describing drug elimination from the body most accurately describes the pharmacokinetics of mibefradil in dogs. The new fractal reaction order can be explained in terms of the complex geometry of the liver, the organ responsible for eliminating the drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.